Evidence map›Paper›PMID 41158291›Full record

ArticleMedical review (2021)2025

Orchestration of tertiary lymphoid structures: decoding developmental mechanisms for next-generation cancer immunotherapies.

Wenqin Hao, Ying Zhao

Abstract read
In one paragraph

Article in Medical review (2021), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Wenqin HaoBeijing Key Laboratory of Protein Posttranslational Modifications and Cell Function, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.ORCID https://orcid.org/0009-0002-2716-4200
Ying ZhaoBeijing Key Laboratory of Protein Posttranslational Modifications and Cell Function, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tertiary lymphoid structures (TLSs) are ectopic lymphoid aggregates that form in non-lymphoid organs, frequently observed in conditions such as cancer, autoimmune diseases, transplant rejection, and chronic inflammation. Growing evidence suggests that TLSs are beneficial for patients' prognosis with higher TLS density generally correlating with improved therapeutic response and survival outcomes across malignancies and might serve as a novel therapeutic target for cancer immunotherapy. However, the correlation between TLSs and tumor development is still ambiguous. The exact timing of TLS formation during tumorigenesis and their dynamic evolution throughout tumor progression remain under investigation. Recent studies have identified potential strategies for inducing TLSs, but there remains a considerable distance from clinical application. More advanced techniques such as high-resolution spatial multi-omics technologies combined with big data analysis will benefit understanding the complex interactions within TLSs and developing novel immunotherapies.

Indexed as

cancerimmunotherapytertiary lymphoid structures

Identifiers

PMID41158291
PMCPMC12558035

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.